I would imagine that between the well seasoned professional lobbyists and the "rookie" lobbyists and various politicians, experienced reputable biotech people and well meaning investment board civilians, Ms Woodcock must hear more than her fair share of chirping. It's probably all she can handle to disregard the lowly opinions of the investment community (noisy but insistent) and rely on the trial results (just the facts, if you please) and trusted consultants. I imagine it would be like listening to a baseball game on a cheap radio with a missing antenna...mostly static. Sorry if this offends anyone but I'm in the same boat as everybody here, not important enough to matter.